Kisspeptin is a naturally occurring family of peptide hormones encoded by the KISS1 gene. The precursor protein is cleaved into several biologically active peptides, including kisspeptin-54 (metastin), kisspeptin-14, kisspeptin-13, and kisspeptin-10. These peptides all bind to the KISS1 receptor (KISS1R/GPR54) and play a central role in regulating the reproductive endocrine system.
Kisspeptin is considered the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. It stimulates hypothalamic neurons to release gonadotropin-releasing hormone (GnRH), which subsequently increases secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. These hormones regulate testosterone production, estrogen production, ovulation, spermatogenesis, and fertility.
Over the past decade, kisspeptin has become an area of significant clinical research for infertility, reproductive disorders, delayed puberty, hypothalamic hypogonadism, and sexual dysfunction. However, kisspeptin is not FDA-approved for any medical indication in the United States.
Kisspeptin binds to the KISS1 receptor (GPR54) located on hypothalamic GnRH neurons.
Activation of this receptor results in:
Unlike exogenous testosterone or gonadotropins, kisspeptin works upstream by stimulating the body’s normal reproductive hormone axis. Research also suggests kisspeptin may influence emotional processing, sexual behavior, metabolism, and energy balance through actions within the central nervous system.
Published research suggests kisspeptin may have several potential clinical applications.
Potential benefits may include:
Recent randomized clinical trials have demonstrated improvements in physiological and neural measures of sexual desire in men with hypoactive sexual desire disorder following kisspeptin administration, although additional research is needed before clinical use can be recommended.
Kisspeptin has generally been well tolerated in early human clinical studies, but long-term safety remains under investigation.
Potential adverse effects include:
Because kisspeptin directly influences reproductive hormone signaling, prolonged or inappropriate administration may alter normal GnRH pulsatility. Long-term safety has not yet been established.
Formal contraindications have not been established because kisspeptin remains investigational.
Based on current knowledge, kisspeptin should generally be avoided or used only with specialist supervision in individuals with:
Individuals with infertility or endocrine disorders should undergo evaluation by a reproductive endocrinologist or other qualified healthcare provider before receiving investigational kisspeptin therapy.
Kisspeptin is NOT FDA-approved for any medical indication in the United States.
It is not FDA-approved for:
Although several clinical trials have demonstrated promising physiologic effects, therapeutic protocols remain investigational and have not been incorporated into standard clinical practice.
Human Studies
Kisspeptin has one of the more robust human research programs among investigational reproductive peptides.
Human clinical studies have evaluated kisspeptin for:
Published studies demonstrate that kisspeptin reliably stimulates LH and FSH release in healthy adults and in selected patients with reproductive disorders. More recent randomized clinical trials have demonstrated increased penile tumescence, enhanced sexual brain processing, and improvements in behavioral measures of sexual desire in men with hypoactive sexual desire disorder.
Animal & Preclinical Studies
Animal studies have demonstrated that kisspeptin:
These studies established kisspeptin as the principal upstream regulator of mammalian reproductive endocrinology and provided the foundation for ongoing human clinical trials.
Human Studies
Animal & Preclinical Studies
Review Articles
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
Kisspeptin is not FDA-approved for any medical indication in the United States. Although clinical research has demonstrated promising effects on reproductive hormone regulation and fertility, its therapeutic use remains investigational. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# Gonadorelin